Letters by company
Capital One Financial CORP
10 letters discussing COF. Everything written about it on this site is on its ticker page.
- RGA Investment Advisors The Great Divide: Why the Stock Market is So Concentrated and Where We Are Finding Opportunities Alphabet anchors the portfolio’s AI thesis, with RGA arguing that its proprietary chips, datacenters, models, consumer distribution and cloud business make it uniquely vertically integrated. Capital One was added after its Discover acquisition, which RGA expects to create a scaled payments network, improve its loan mix and support substantial capital returns. Q3 2025 COF $120BGOOGL $4.2T
- Polaris Capital Management First Quarter 2026 Global Equity Composite Commentary Polaris Global Equity Composite exited Methanex, Sally Beauty, UnitedHealth and Capgemini as valuations or investment theses changed, while initiating Eastman Chemical and Ryanair. The portfolio favors global diversification and selective buying amid oil-driven volatility, with Ryanair's cost structure and Eastman's restructuring viewed as near-term catalysts. First Quarter 2026 ALSN $9.6BARW $12BCAPMF $21B
- Davis Opportunity Fund Davis Opportunity Fund Annual Review 2026 Davis Opportunity Fund argues that concentrated, expensive passive indexes warrant a selective active approach, with reduced exposure to richly valued megacap technology. The portfolio added managed-care insurers after cost-driven weakness, trimmed selected Magnificent 7 holdings, and emphasizes Capital One, Wesco International, Coterra and Teck Resources as undervalued or structurally advantaged holdings. 2025 AMAT $404BCOF $120BUNH $338B
- Artisan Partners Artisan Global Opportunities Fund Quarterly Commentary Artisan Global Opportunities Fund added RTX, Capital One, Somnigroup, L3Harris and BAE Systems while exiting several Garden investments whose theses were not progressing. The portfolio emphasizes health care franchises, defense suppliers and AI infrastructure beneficiaries, while maintaining valuation discipline around Oracle and reducing Netflix, Snowflake and Boston Scientific. Q4 2025 ARGNF $59BBAESY $72BBSX $61B
- Sequoia Fund Year-End 2025 Sequoia Fund Letter Sequoia Fund trimmed Rolls-Royce and Alphabet after their weightings and valuations rose, while retaining both as its largest holdings. It added to Elevance and built new positions in MSA Safety, Accenture, and Align Technology, arguing that each combines a durable franchise with a temporary source of market concern or a favorable valuation. 2025 GOOGL $4.2TRLLCF $87BACN $118B
- Davis Advisors Global ADR Davis Global ADR SMA Portfolio Summer Update 2026 Davis Global ADR SMA retained its contrarian Chinese exposure, arguing that sound company fundamentals and low valuations outweigh the market's AI-driven preference for technology leaders. The portfolio discussed Meituan, AIA Group, Entain, Capital One and the Devon Energy combination, while paring selected semiconductor positions on valuation. first half of 2026 —
- Oakmark Funds The discipline to stay boring Oakmark Fund declined to chase AI hardware leaders despite their dominance in value indexes, arguing that uncertain durability of elevated margins leaves insufficient margin of safety. The fund favors discounted businesses such as Corebridge Financial and expects holdings including Capital One, AIG, Alphabet and Amazon to benefit from AI adoption. 2Q 2026 CRBG $15B
- Polaris Capital Management Fourth Quarter 2025 Global Equity Composite Commentary Polaris Global Equity Composite sold Vipshop, Carlyle, Magna, Novartis and Sony Financial after targets were reached, then deployed proceeds into Alibaba, AIA and Ping An to capture Asian e-commerce, cloud and insurance demand. The portfolio favored cash-generative picks-and-shovels businesses and diversification beyond the U.S., citing opportunities in Asian AI supply chains, European industry and financials. FOURTH QUARTER 2025 BABA $270BLNTH $6.5BSKHY $943B
- Patient Capital Management Samantha's Quarterly Letter Opportunity Equity argues that tariff policy has raised recession risk, but negotiated trade deals could stabilize markets and preserve the secular bull case. The portfolio added back airline exposure after trimming it during strength, and favors Nvidia, Amazon, Alphabet and Meta alongside cyclical travel names priced for a downturn. 1Q25 NVDA $5.8TAMZN $2.7TDAL $54B
- Patient Capital Management 2Q24 Portfolio Activity and Attribution Patient Opportunity Equity increased exposure to underfollowed health-care and smaller-company opportunities while finding several Magnificent 7 holdings closer to fair value. It entered Everi Holdings and exited Capital One and Uber. The portfolio argues that Illumina, Biogen and Royalty Pharma offer mispriced health-care upside, while Everi’s IGT transaction should create a stronger casino-technology platform. 2Q24 AMZN $2.7TBIIB $33BCOIN $47B
